polymyalgia rheumatica
DiseaseWikipedia
63
MENTIONS
13
EPISODES
12
PODCASTS
Search complete. 63 mentions across 13 episodes found for "polymyalgia rheumatica".
Oct 31, 2026
Ep. 201 Part 1 | Lyme Disease The Hidden Driver of Chronic Disease - Dr. Richard Horowitz
R
15:14Richard HorowitzGUEST
So you've got to look at that full multisystemic picture when you're trying to differentiate, for example, a rash that's a ringworm or a cellulitis versus something that's a Lyme rash where you now have these multisystemic manifestations.
K
15:25Kerry GelbHOST
How about like PMR, polymyalgia rheumatica? Sometimes that pain will migrate.
R
15:32Richard HorowitzGUEST
So I've only seen a couple of cases in my lifetime.
R
15:34Richard HorowitzGUEST
I've been doing medicine for 42 years with 13,000 people.
R
15:39Richard HorowitzGUEST
Usually with PMR, the SED rate is going to be 80, 90, 100, right? I mean, you get this massive inflammatory response.
R
15:46Richard HorowitzGUEST
I've only seen a handful of cases of it.
R
15:48Richard HorowitzGUEST
And in a lot of cases, there might have been some overlapping autoimmune manifestations.
R
15:54Richard HorowitzGUEST
I'd have to do a search for you on that one.
Mixed Drinks, Mixed Results (10.30.2026)
J
0:19Jack CushHOST
a special edition since it's the day before Halloween, and I'm Jack Cush wearing a goofy Halloween cap.
J
0:28Jack CushHOST
This week on the podcast, new guidelines for PMR, certainty about good and bad beverages in gout, mixed results, and Sjogren's.
J
0:40Jack CushHOST
Non-lupus drugs save lupus lives and big hips sink ships in psoriatic arthritis.
J
0:48Jack CushHOST
If you can decipher that, you'll know everything about rheumatology.
J
0:54Jack CushHOST
At the top.
J
0:55Jack CushHOST
Novartis announced this past week that the European Commission has approved Cosentix secukinumab for use in adults with polymyalgia rheumatica.
J
1:05Jack CushHOST
That would be adults with PMR not responding to or intolerant of glucocorticoids.
J
1:12Jack CushHOST
This makes secukinumab the first IL-17A inhibitor approved in Europe for PMR.
Greg Pain: The do's and dont's of Osteoporosis
G
32:14Greg PainGUEST
hardware.
T
32:15Tim BeveridgeHOST
I've had two full knee replacements at 45 and 54 Hashimoto's since age 14 and diagnosed PMR.
T
32:21Tim BeveridgeHOST
Crikey.
T
32:22Tim BeveridgeHOST
What strength exercises would you recommend once past three months post-surgery? The bone health's overall, but definitely density and more autoimmune issues developing caused by thyroid hormones.
Greg Pain: The do's and dont's of Osteoporosis
G
32:14Greg PainGUEST
hardware.
T
32:15Tim BeveridgeHOST
I've had two full knee replacements at 45 and 54 Hashimoto's since age 14 and diagnosed PMR.
T
32:21Tim BeveridgeHOST
Crikey.
T
32:22Tim BeveridgeHOST
What strength exercises would you recommend once past three months post-surgery? The bone health's overall, but definitely density and more autoimmune issues developing caused by thyroid hormones.
Advanced Practice Under The Spotlight - Andy McDonough
A
5:35Andy McDonoughGUEST
You can get really instant feedback on your cases.
A
5:37Andy McDonoughGUEST
So you think someone's got PMR.
A
5:39Andy McDonoughGUEST
You think somebody's got an infection.
A
5:40Andy McDonoughGUEST
You get your blood back in an hour, not in a week.
Exploring Heart Rate Variability and Vagus Nerve Stimulation in Rheumatoid Arthritis Management
C
55:26Clint PattisonHOST
Does this also work for
J
55:27Jose PandoGUEST
PMR? Technically, it could be, but I don't think that there's other medications that you can use that are more easily accessible and less expensive.
C
55:38Clint PattisonHOST
So would you, at the moment, just for now, would you consider this particularly implantable device something that is a last resort or something as a workaround when conventional treatment fails, rather than something that is going to be a first-line approach for anyone?
J
56:01Jose PandoGUEST
Like, if you look at traditionally how things have worked, and we have been doing this for a long time, is that you use with your sicker patients, and when you feel more comfortable and see the response, and you say, oh my goodness, this can work better for this or that type of patients, you begin to use it more broadly.
Episode 353 - Martin Smith on Tackling Water Companies and Pollution
M
50:25Martin SmithGUEST
I was seriously ill.
M
50:26Martin SmithGUEST
I had PMR and giant cell arteritis.
M
50:28Martin SmithGUEST
My wife had had breast cancer.
M
50:30Martin SmithGUEST
She had two hip operations that have gone completely wrong.
Internal Medicine: Musculoskeletal Topics (Ep 7)
S
9:22speaker_0HOST
How do you confirm the diagnosis of polyarteritis nodosa? Biopsy or angiogram.
S
9:34speaker_0HOST
Polymyalgia rheumatica is strongly associated with which other type of vasculitis? Temporal arteritis or giant cell arteritis.
S
9:51speaker_0HOST
Define CREST syndrome.
S
10:01speaker_0HOST
Calcinosis, Raynaud's, esophageal dysmotility, sclerodactyly, and telangiectasia.
8 MINS LATER
S
18:05speaker_0HOST
She also complains of fatigue and fever.
S
18:08speaker_0HOST
Labs show a markedly elevated erythrocyte sedimentation rate.
S
18:12speaker_0HOST
What is the most likely diagnosis? Polymyalgia rheumatica.
S
18:24speaker_0HOST
What is the treatment for scleroderma? There is no specific treatment, but you can treat the individual symptoms.
Don’t Hold the JAK (10.9.2026)
J
12:02Jack CushHOST
We have a bunch of reports on vasculitis and a report- a few reports on avacopan.
J
12:07Jack CushHOST
Let's start with discussion of PMR, a Danish national study of fifty-one thousand PMR patients.
J
12:15Jack CushHOST
Um, half managed by primary care, half managed by secondary care MDs, I would assume that's rheumatologists.
J
12:23Jack CushHOST
The incidence of PMR is a hundred and twelve cases per hundred thousand.
J
12:28Jack CushHOST
That seems to be on par.
J
12:31Jack CushHOST
Um, but the incidence over time, they did this between, um, over the years, uh, ten-year ic- interval, um, between them.
J
12:41Jack CushHOST
But the incidence of PMR in primary care went down, but increased in secondary care.
J
12:47Jack CushHOST
Hmm.
RhAPPcast: The Steroid Tightrope: Managing GC Toxicity in PMR
A
0:00Amanda MixonHOST
[intro music] Welcome to RapCast, the official podcast of Rheumatology Advanced Practice Providers, where we bring together expert perspectives, practical insights, and meaningful conversations shaping rheumatology care today.
A
0:28Amanda MixonHOST
I'm Amanda Mixon, and I am very excited to welcome you to today's episode, "The Steroid Tightrope: Managing Glucocorticoid Toxicity in PMR." This podcast is a clinical review of current approaches to the treatment of polymyalgia rheumatica, inclusive of treat to target strategy, the value of leveraging treatment based on glucocorticoid use according to the guidelines, and elements that should be taken into consideration in patients that do not achieve treatment goals, such as control of signs and symptoms and remission.
A
1:05Amanda MixonHOST
Glucocorticoids remain the cornerstone of treatment for polymyalgia rheumatica, often delivering a rapid and dramatic symptom relief for patients.
A
1:15Amanda MixonHOST
Because of the trade-off between the benefits and challenges of steroid use, it's critical to balance the gain against the potential harms.
A
1:24Amanda MixonHOST
About half of the patients diagnosed with PMR and treated with glucocorticoids do achieve clinical response within the time and dose framework defined in the current guidelines.
A
1:36Amanda MixonHOST
However, as every rheumatology provider knows, that relief can come with a cost.
A
1:42Amanda MixonHOST
Many patients struggle with prolonged steroid exposure, taper-related relapses, and the cumulative burden of glucocorticoid toxicity.
A
1:51Amanda MixonHOST
This can be anything from metabolic and cardiovascular complications to osteoporosis, infection risk, and just overall impacts on the quality of life.
3 more episodes mention polymyalgia rheumatica.
Create an account to see the whole feed, search across every transcript, and follow the entities you care about.